Please login to the form below

Not currently logged in

Ann Barbier joins Translate Bio as its chief medical officer

She will take responsibility for leading the US biotech's clinical R&D

Ann BarbierUS-based biotech Translate Bio has appointed Ann Barbier as its new chief medical officer.

She brings 20 years' of drug discovery and development experience to her new role, which will see her take responsibility for leading all clinical research and development, medical affairs and related functions at Translate Bio.

She said: “With near-term clinical programmes in cystic fibrosis and OTC deficiency, Translate Bio is approaching a critical and exciting time.

“Our platform has the potential to be transformative for patients, and I am incredibly excited about the opportunity to join an experienced management team dedicated to finding innovative treatments in areas of high unmet need.”

Prior to joining Translate Bio, Barbier was vice president of clinical development, rare genetic diseases at Agios Pharmaceuticals, where she led the development programme of a small molecule in rare benign haematological diseases.

She has also served Shire in various roles including global clinical development lead and senior medical director, and her career experience has seen her work at Envivo, Johnson & Johnson and Aventis.

15th November 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...